Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System

Reporting System ◽

Biologic Therapy ◽

Cell Lymphoma ◽

Adverse Event Reporting ◽

Event Reporting ◽

Hepatosplenic T Cell Lymphoma ◽

Hepatosplenic T-Cell lymphoma on Biologic Therapy for Inflammatory Bowel Disease: A Systematic Review of the Literature and FDA Adverse Event Reporting System

The American Journal of Gastroenterology ◽

10.14309/00000434-201710001-00700 ◽

2017 ◽

Vol 112 ◽

pp. S387

Author(s):

Eric D. Shah ◽

Anil Nayyar ◽

Kerry Jo Lee

Keyword(s):

Systematic Review ◽

Reporting System ◽

Biologic Therapy ◽

Cell Lymphoma ◽

Adverse Event Reporting ◽

Review Of The Literature ◽

Event Reporting ◽

Hepatosplenic T Cell Lymphoma ◽

Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2013.04.031 ◽

2013 ◽

Vol 69 (3) ◽

pp. 393-398 ◽

Cited By ~ 16

Author(s):

Derrick J. Stobaugh ◽

Parakkal Deepak ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Food And Drug Administration ◽

Adverse Event Reporting ◽

Event Reporting ◽

Su1158 Risk of Leukemia With Pharmacotherapy Among Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(13)61525-5 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-414

Author(s):

Parakkal Deepak ◽

Derrick J. Stobaugh ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Food And Drug Administration ◽

Adverse Event Reporting ◽

Event Reporting ◽

Concomitant Antibiotic Usage Does Not Further Increase the Risk of Inflammatory Bowel Disease with Isotretinoin Treatment for Acne: A Review of the Food and Drug Administration Adverse Event Reporting System

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-01596 ◽

2012 ◽

Vol 107 ◽

pp. S645

Author(s):

Derrick Stobaugh ◽

Parakkal Deepak ◽

Eli Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Antibiotic Usage ◽

Event Reporting ◽

Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn’s disease medications and hepatosplenic T-cell lymphoma

Systematic Reviews ◽

10.1186/2046-4053-2-53 ◽

2013 ◽

Vol 2 (1) ◽

Cited By ~ 16

Author(s):

Saranya A Selvaraj ◽

Elizabeth Chairez ◽

Lisa M Wilson ◽

Mark Lazarev ◽

Eric B Bass ◽

...

Keyword(s):

Adverse Event ◽

T Cell ◽

Systematic Reviews ◽

Reporting System ◽

Cell Lymphoma ◽

Case Reports ◽

Adverse Event Reporting ◽

Event Reporting ◽

Hepatosplenic T Cell Lymphoma

Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS)

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-01583 ◽

2012 ◽

Vol 107 ◽

pp. S638-S639

Author(s):

Derrick Stobaugh ◽

Parakkal Deepak ◽

Muhammed Sherid ◽

Eli Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Food And Drug Administration ◽

Adverse Event Reporting ◽

Event Reporting ◽

Mo1198 Risk of Pancreatitis With Tumor Necrosis Factor-Alpha Inhibitors Among Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(14)62114-4 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-583-S-584

Author(s):

Derrick J. Stobaugh ◽

Salih Samo ◽

Parakkal Deepak ◽

Eli D. Ehrenpreis

Keyword(s):

Tumor Necrosis ◽

Reporting System ◽

Adverse Event Reporting ◽

Necrosis Factor Alpha ◽

Event Reporting ◽

Inflammatory Bowel ◽

Factor Alpha ◽

Necrosis Factor

Su1149 Drug Induced Lupus (DIL) With Adalimumab and Certolizumab in Infliximab Naïve Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(13)61516-4 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-411-S-412 ◽

Cited By ~ 1

Author(s):

Parakkal Deepak ◽

Derrick J. Stobaugh ◽

Brett D. Riederman ◽

Eli D. Ehrenpreis

Keyword(s):

Adverse Event ◽

Drug Administration ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Drug Induced ◽

Event Reporting ◽

Su1161 Risk of Solid Cancers With Tumor Necrosis Factor Alpha Inhibitor Therapy Among Inflammatory Bowel Disease Patients: An Analysis of the Food and Drug Administration Adverse Event Reporting System

Gastroenterology ◽

10.1016/s0016-5085(13)61528-0 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-416

Author(s):

Derrick J. Stobaugh ◽

Parakkal Deepak ◽

Eli D. Ehrenpreis

Keyword(s):

Tumor Necrosis ◽

Reporting System ◽

Adverse Event Reporting ◽

Necrosis Factor Alpha ◽

Event Reporting ◽

Inflammatory Bowel ◽

Factor Alpha ◽

Necrosis Factor

Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-018-03763-5 ◽

2019 ◽

Vol 83 (3) ◽

pp. 599-601 ◽

Cited By ~ 3

Author(s):

Huaqiang Zhou ◽

Jiaqing Liu ◽

Yaxiong Zhang ◽

Li Zhang

Keyword(s):

Adverse Event ◽

Combination Treatment ◽

Bowel Disease ◽

Reporting System ◽

Adverse Event Reporting ◽

Event Reporting ◽